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Cholangiocarcinoma is a predominantly fatal cancer, which can be diﬃcult to treat. It has been reported that the administration
of pioglitazone temporarily improved not only diabetic control, but also bile duct carcinoma-induced cholangiohepatitis.
Pioglitazone is considered to have both direct and indirect mechanisms of action on the tumor-related hepatitis. Several
molecules induced by thiazolidinedione, including Smad pathway-related molecules, adipokines, and other lipid metabolism-
related proteins, may directly or indirectly suppress tumor development and/or tumor-induced cholangiohepatitis. Although
the most frequent and critical side eﬀect of thiazolidinedione is drug-induced hepatitis, it can probably be avoided by careful
monitoring of serum hepatic enzyme levels. Thiazolidinedione should be considered for management of tumor-induced hepatitis
in the presence of diabetes unless severe side eﬀects occur.
Copyright © 2008 S. Suzuki and K. Hashizume.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The primary eﬀects of thiazolidinedione, a peroxisome pro-
liferator-activated receptor γ (PPARγ)agonist, are the reduc-
tion of insulin resistance and improvement of insulin
sensitivity, resulting in reduction of fasting plasma glucose,
insulin, and free fatty acid levels [1].
Cholangiocarcinoma is a predominantly fatal cancer,
which can be diﬃcult to treat. We reported previously that
administration of the thiazolidinedione, pioglitazone, in a
73-year-old male patient who developed cholangiocarci-
noma with cholangiohepatitis and diabetes improved not
only diabetic control, but also the tumor-induced cholan-
giohepatitis, and improved the patient’s quality of life [2].
One and half years after treatment, the patient again showed
deterioration of cholangiohepatitis and diabetic control. He
ﬁnally died of obstructive jaundice.
There are two possible mechanisms to explain the initial
improvement of hepatitis in our case: the PPARγ ligand may
have directly suppressed the abnormal cell growth, or the
PPARγ ligand may have indirectly suppressed tumor growth
after the ligand improved hepatitis and/or diabetes.
In this review, we discuss the mechanisms of the tem-
porary beneﬁcial eﬀects of the agent, especially the above
two possibilities, with regard to the literature concerning
PPARγ and cholangiohepatitis. In addition, we also discuss
the positive choice of thiazolidinedione, despite elevated
serum concentrations of hepatic enzymes.
2. DIRECT EFFECTS ON THE DEVELOPMENT
OF CHOLANGIOCARCINOMA
These mechanisms were supported by the results of basic
experiments using various cholangiocarcinoma cell lines [3–
6]. PPARγ ligand mediates the inhibition of cholangiocar-
cinoma cell growth through p53-dependent mechanisms
[3]. The PPARγ ligand, 15-deoxy-delta 12,14-PGJ2, induces
apoptosis in cholangiocarcinoma cell lines although regu-
lation of apoptosis-related protein expression varies [4, 5],
while artiﬁcial regulation of PPARγ expression in cholan-
giocarcinoma cell lines suggests that PPARγ may actually
promote tumor cell growth viathe Smad pathway [6]. It has
been reported that PPARγ ligands can suppress prolifera-
tion and induce apoptosis although PPARγ itself may have2 PPAR Research
divergent eﬀects on cellular growth in cholangiocarcinoma
cell lines [7].
3. INDIRECT EFFECTS ON THE DEVELOPMENT
OF CHOLANGIOCARCINOMA
Thiazolidinedione seems not to improve insulin sensitivity
and glucose disposal by direct eﬀects on either the liver
or muscle. PPARγ is expressed preferentially in adipose
tissue, and its levels of expression in the liver and skeletal
muscle are low [8]. Thus, it is more likely that the primary
eﬀects of these drugs are on adipose tissue, followed by
secondary beneﬁts on other target tissues of insulin [9]. In
our case, there was no evidence that pioglitazone directly
reduced the tumor size. In contrast, cholangiohepatitis was
improved by administration of this agent. In addition, the
progressive cholangiohepatitis was probably related to the
cholangiocarcinoma. In general, cholangiocarcinoma de-
velopment is based possibly upon the cytotoxicity of bile
constituents, that is, cytotoxic bile acids and lysolecithins.
These humoral factors may aﬀect tumor progression. Thus,
itwassuggestedthatpioglitazoneindirectlyimprovescancer-
mediated inﬂammation, such as cholangiohepatitis, rather
than directly suppressing tumor growth.
As mentioned above, it is now generally accepted that
adipose cells send molecular signals, including cytokines,
to other tissues. Thus, it is possible that PPARγ activation
controls one or more genes that regulate systemic tumor
promotion (see Figure 1). The interesting candidate genes in
this regard are TNF-α, adiponectin, and leptin. Other lipid-
related genes regulated by PPARγ ligands,suchaslipoprotein
lipase and fatty acid binding protein, may also control tumor
development [10].
3.1. TNF-α
Thiazolidinedione reduces TNF-α expression in human and
rodent adipocytes [11]. A series of studies using cho-
langiocarcinoma cell lines demonstrated that TNF-α itself
attenuates the growth of cholangiocarcinoma cells and
induces apoptosis [11–13]. However, several recent studies
have demonstrated that TNF-α promotes invasiveness and
accelerates migration of cholangiocarcinoma cells [14–16].
These observations imply that the suppression of TNF-α
production may attenuate the progressive invasion of tumor
cells into healthy hepatobiliary cells.
3.2. Adiponectinandleptin
PPARγ agonists have been reported to increase the expres-
sion and circulating levels of adiponectin, an adipocyte-
derived protein with insulin-sensitizing activity [17], in
diabetic rodents and in patients with type 2 diabetes [18].
There have been many reports, especially in breast cancer,
that adiponectin plays roles in the inhibition of tumor cell
growth[19].Theexpressionofleptin,asuppressoroffeeding
behavior, is negatively regulated by thiazolidinediones [20].
Leptin has been reported to induce tumor development
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Figure 1: Inhibitory eﬀects of PPARγ ligand on the development
of cholangiocarcinoma. PPARγ ligand directly suppresses tumor
progression through p53 and Smad pathways (red arrow) and
also stimulates adipocyte and hepatobiliary cells (gray arrow).
Secretion of adipokines (TNF-α, adiponectin, and leptin) and
production of lipid-related proteins (FABP and LPL) are reg-
ulated by PPARγ ligand. Up- and downregulation of various
gene signals from adipocytes (yellow line) and hepatobiliary cells
(broken line) promoted suppression of tumor growth. As a result,
PPARγ indirectly suppressed tumor growth of cholangiocarcinoma
through adipocytes and hepatobiliary cells. Currently, evidence of
suppressive signals from hepatobiliary cells to cholangiocarcinoma
is unavailable (broken line). FABP: fatty acid binding protein, LPL:
lipoprotein lipase, TNF-α: tumor necrosis factor-α.
in breast cancer [21], suggesting that suppression of leptin
secretion may reduce tumor progression.
3.3. Otherlipid-relatedproteins
Other lipid-related proteins, such as lipoprotein lipase (LPL)
and fatty acid binding proteins (FABPs), are positively
regulatedbythePPARγ ligandGW1929[22].Althoughthere
have been no studies related to cholangiocarcinoma and
these lipid-associated proteins, there is a great deal of evi-
dence that the proteins promote reduction of tumor growth.
Intestinal polyp formation was suppressed by increasing
LPL activity [23]. As FABPs play roles not only as lipid
chaperones but also as free radical scavengers, the molecules
may aﬀect tumor progression through the oxidative stress
pathways. The protein expression of liver FABP was reduced
in neoplastic lesions of CuZn superoxide dismutase-deﬁcient
mice [24]. It has been reported that FABP reduces cellular
damage from hypoxia/reoxygeneration [25]. These lipid-
relatedproteinsmayalsoplayrolesinthereductionoftumor
growth and/or suppression of tumor-mediated liver damage.
4. HEPATIC SIDE EFFECTS
The most frequent and critical side eﬀect of thiazolidine-
dione that must be taken into consideration before starting
thiazolidinedione administration in cases of cholangiocar-
cinoma is drug-induced hepatitis. Although some dataS. Suzuki and K. Hashizume 3
are available from animal studies suggesting that hepatic
toxicity may be a characteristic of the thiazolidinedione class
[26], current clinical evidence indicates that pioglitazone
treatment does not result in liver toxicity [27]. However,
this agent causes mild transient increases in serum ALT
levels. The FDA recommends monitoring ALT levels and
not using these drugs in patients with liver disease [28].
Moreover,itwasreportedthatpatientsreceivingpioglitazone
maydevelopseriousliverinjuryandshouldbemonitoredfor
evidence of hepatitis [29].
Unlike other existing antidiabetic medications that show
a very rapid onset of activity, pioglitazone and rosiglitazone
exhibit a characteristic delay of 4–12 weeks in the onset
of their therapeutic eﬀects. It has been suggested that
thiazolidinedioneshouldbecontinuedforatleastonemonth
to obtain results. In our case, initial improvement of the
elevated hepatic enzymes was observed two weeks after
startingadministrationofthisagent.Thesedataindicatethat
the eﬀectiveness in cases of tumor-related hepatitis could
be assessed within two weeks rather than 4–12 weeks when
diabetic control is obtained.
5. PERSPECTIVES
Taken together with these considerations, as PPARγ ligands
are probably eﬀective in the suppression of tumor devel-
opment, especially on the reduction of tumor invasiveness
through molecular signals from adipocytes, thiazolidine-
dione should be chosen not only for diabetic control, but
also as an attenuator of tumor progression in patients
with diabetes. Drug-induced hepatitis can be avoided by
meticulous monitoring of serum hepatic enzyme levels.
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